Albumin-bound Paclitaxel: in metastatic breast cancer.


:A new formulation of paclitaxel, 130-nanometre albumin-bound paclitaxel (nab-paclitaxel), solubilises hydrophobic paclitaxel and may increase paclitaxel delivery to tumour cells. Intravenous nab-paclitaxel 260 mg/m(2) had a higher maximum whole-blood concentration, shorter time to peak concentration, larger distribution volume and greater clearance than a 175 mg/m(2) dose of a conventional polyoxyethylated castor oil (Cremophor EL) solublised paclitaxel (CrEL-paclitaxel). The reconciled target-lesion response rate was significantly higher in patients receiving intravenous nab-paclitaxel 260 mg/m(2) once every 3 weeks than in those receiving CrEL-paclitaxel 175 mg/m(2) once every 3 weeks (21.5% vs 11.1%) in a randomised, nonblind, phase III trial in 454 patients with metastatic breast cancer. The objective response rate (ORR) was also significantly greater in nab-paclitaxel than in CrEL-paclitaxel recipients (33% vs 19%). In noncomparative phase II trials, ORRs of 48% and 51% were observed in patients receiving nab-paclitaxel 175 or 300 mg/m(2) once every 3 weeks. nab-Paclitaxel 260 mg/m(2) caused less grade 4 neutropenia than CrEL-paclitaxel 175 mg/m(2). The incidence of grade 3 sensory neuropathy was higher in nab-paclitaxel recipients, reflecting the higher dosage of nab-paclitaxel, and improved with treatment interruption. Despite the absence of corticosteroid and antihistamine premedication, no severe hypersensitivity reactions were reported.






Robinson DM,Keating GM




Has Abstract


2006-01-01 00:00:00
















  • Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

    abstract::Gatifloxacin (Tequin) is an 8-methoxy fluoroquinolone approved in the US for use in the treatment of community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute sinusitis, uncomplicated and complicated urinary tract infections (UTIs), pyelonephritis, gonorrhoea and uncomplicated skin an...


    pub_type: 杂志文章,评审


    authors: Keam SJ,Croom KF,Keating GM

    更新日期:2005-01-01 00:00:00

  • Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.

    abstract::Cilazapril is an orally active angiotensin converting enzyme (ACE) inhibitor which lowers peripheral vascular resistance without affecting heart rate. Like enalapril and ramipril it is a prodrug, and is hydrolysed after absorption to cilazaprilat, which has a long terminal phase elimination half-life permitting once d...


    pub_type: 杂志文章,评审


    authors: Deget F,Brogden RN

    更新日期:1991-05-01 00:00:00

  • Enasidenib: First Global Approval.

    abstract::Enasidenib (Idhifa®) is an oral isocitrate dehydrogenase-2 (IDH2) inhibitor developed by Celgene Corporation under a global, exclusive license from Agios Pharmaceuticals. Enasidenib has been approved in the USA for the treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) and an IDH2 mutation a...


    pub_type: 杂志文章,评审


    authors: Kim ES

    更新日期:2017-10-01 00:00:00

  • Pregabalin: in the treatment of painful diabetic peripheral neuropathy.

    abstract::Pregabalin, the pharmacologically active S-enantiomer of 3-aminomethyl-5-methyl-hexanoic acid, has a similar pharmacological profile to that of its developmental predecessor gabapentin, but showed greater analgesic activity in rodent models of neuropathic pain. The exact mechanism of action of pregabalin is unclear, a...


    pub_type: 杂志文章,评审


    authors: Frampton JE,Scott LJ

    更新日期:2004-01-01 00:00:00

  • Nateglinide.

    abstract::Nateglinide is a novel D-phenylalanine derivative that inhibits ATP-sensitive K+ channels in pancreatic beta-cells in the presence of glucose and thereby stimulates the prandial release of insulin. Nateglinide reduces fasting and mealtime blood glucose levels in animals, healthy volunteers, and patients with type 2 (n...


    pub_type: 杂志文章,评审


    authors: Dunn CJ,Faulds D

    更新日期:2000-09-01 00:00:00

  • Atenolol with and without nifedipine in the treatment of angina pectoris. Preliminary report.

    abstract::Atenolol and nifedipine have been shown to be effective single agents in angina pectoris, but reports suggest that additional benefits may be conferred by combining the 2 drugs. Therefore, to establish that the combination regimen was at least as effective as either atenolol or nifedipine alone, a multicentre study wa...


    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Sandberg M,Foale RA

    更新日期:1988-01-01 00:00:00

  • Management of gastroenteritis in early childhood.

    abstract::The most important aspect of modern management of acute diarrhoeal illness in children is that of oral rehydration therapy, and drug therapy is very rarely indicated. Despite the dramatic decline in mortality and morbidity in recent years, there is still the need for continuing education in the appropriate use of oral...


    pub_type: 杂志文章,评审


    authors: Davies A,Jenkins HR

    更新日期:1992-07-01 00:00:00

  • Guillain-Barré syndrome: epidemiology, pathophysiology and management.

    abstract::Guillain-Barré syndrome (GBS) is clinically defined as an acute peripheral neuropathy causing limb weakness that progresses over a time period of days or, at the most, up to 4 weeks. GBS occurs throughout the world with a median annual incidence of 1.3 cases per population of 100 000, with men being more frequently af...


    pub_type: 杂志文章,评审


    authors: Kuwabara S

    更新日期:2004-01-01 00:00:00

  • Drug treatment of hypertension.

    abstract::There are several first choices for the treatment of mild and moderate hypertension. The selection of a drug may be influenced by concomitant pathology, with positive indications for particular drugs, e.g. coexistent angina, indicating use of a beta-receptor blocking drug or calcium antagonist; fluid retention indicat...


    pub_type: 杂志文章,评审


    authors: Prichard BN

    更新日期:1988-01-01 00:00:00

  • Osteoarthritis 1991. Current drug treatment regimens.

    abstract::Osteoarthritis, the most common rheumatic disease, presents the clinician with a major therapeutic and management task. The chronic and progressive course of the disease is punctuated by pain, declining function and escalating disability. This article attempts to deal with the pharmacological therapeutic options avail...


    pub_type: 杂志文章,评审


    authors: al Arfag A,Davis P

    更新日期:1991-02-01 00:00:00

  • Impact of smoking on asthma therapy: a critical review of clinical evidence.

    abstract::Airway inflammation is central to the pathophysiology of asthma, with treatment directed towards modification of this inflammation and its consequences. The relationship between cigarette smoking and airway inflammation is also well described, but relatively little data are available on the potential influence of smok...


    pub_type: 杂志文章,评审


    authors: Livingston E,Thomson NC,Chalmers GW

    更新日期:2005-01-01 00:00:00

  • NSAIDs and gastrointestinal cancer prevention.

    abstract::Numerous studies report the relationship between aspirin and other nonsteroidal anti-inflammatories (NSAIDs) and cancer incidence, in particular for colorectal cancer. This paper systematically reviews the evidence of the effect of aspirin and other NSAIDs on the primary prevention of colorectal and other gastrointest...


    pub_type: 杂志文章,评审


    authors: Jolly K,Cheng KK,Langman MJ

    更新日期:2002-01-01 00:00:00

  • Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.

    abstract::Losartan/hydrochlorothiazide (HCTZ) [Hyzaar(R)] is a fixed-dose combination of the angiotensin II receptor antagonist (angiotensin receptor blocker [ARB]) losartan and the thiazide diuretic HCTZ. It is indicated for the treatment of hypertension (including as initial therapy in severe hypertension) and for stroke risk...


    pub_type: 杂志文章,评审


    authors: Keating GM

    更新日期:2009-06-18 00:00:00

  • Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

    abstract::Coronary artery disease and acute myocardial infarction still represent the leading cause of mortality in developed countries. Therefore, great efforts have been made in the last decades to improve reperfusion strategies and adjunctive antithrombotic therapies. In fact, despite optimal epicardial recanalisation, a lar...


    pub_type: 杂志文章,评审


    authors: De Luca G,Savonitto S,van't Hof AW,Suryapranata H

    更新日期:2015-07-01 00:00:00

  • Aspirin for Prevention of Preeclampsia.

    abstract::Aspirin is currently the most widely prescribed treatment in the prevention of cardiovascular complications. The indications for the use of aspirin during pregnancy are, however, the subject of much controversy. Since the first evidence of the obstetric efficacy of aspirin in 1985, numerous studies have tried to deter...


    pub_type: 杂志文章,评审


    authors: Atallah A,Lecarpentier E,Goffinet F,Doret-Dion M,Gaucherand P,Tsatsaris V

    更新日期:2017-11-01 00:00:00

  • Drugs in the treatment of female infertility. Recent advances.

    abstract::Involuntary infertility is an increasing problem in this era of delayed childbearing. Fortunately, many advances have been made recently in the medical and surgical treatment of infertility. This article reviews the principal aetiologies of infertility and their treatments, and focuses on the current and future uses o...


    pub_type: 杂志文章,评审


    authors: Quigley MM

    更新日期:1986-08-01 00:00:00

  • Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.

    abstract::Lefamulin is a novel oral and intravenous (IV) pleuromutilin developed as a twice-daily treatment for community-acquired bacterial pneumonia (CABP). It is a semi-synthetic pleuromutilin with a chemical structure that contains a tricyclic core of five-, six-, and eight-membered rings and a 2-(4-amino-2-hydroxycyclohexy...


    pub_type: 杂志文章,评审


    authors: Zhanel GG,Deng C,Zelenitsky S,Lawrence CK,Adam HJ,Golden A,Berry L,Schweizer F,Zhanel MA,Irfan N,Bay D,Lagacé-Wiens P,Walkty A,Mandell L,Lynch JP 3rd,Karlowsky JA

    更新日期:2020-11-28 00:00:00

  • Are there potential non-lipid-lowering uses of statins?

    abstract::Recent clinical trials have demonstrated beyond doubt that statins are effective in the prevention of acute coronary events. Critical analysis of these studies suggests that the benefits of statin therapy cannot be fully explained on the basis of reductions in plasma cholesterol levels. Accumulating knowledge of the a...


    pub_type: 杂志文章,评审


    authors: Wheeler DC

    更新日期:1998-10-01 00:00:00

  • Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.

    abstract::Bruton's tyrosine kinase (BTK) is crucial in B-cell development and survival. The role of BTK as a downstream kinase in the B-cell receptor (BCR) signaling pathway is well described. As a key player in the pathogenesis of B-cell malignancies, targeting of dysregulated BCR signaling has been explored by development of ...


    pub_type: 杂志文章,评审


    authors: da Cunha-Bang C,Niemann CU

    更新日期:2018-11-01 00:00:00

  • Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.

    abstract::Glatiramer acetate is a synthetic analogue of the multiple sclerosis (MS)-associated antigen, myelin basic protein. It is indicated in the EU, US and many other countries to reduce the frequency of relapses in patients with relapsing-remitting MS (RRMS), and for the treatment of patients who have experienced a well de...


    pub_type: 杂志文章,评审


    authors: Carter NJ,Keating GM

    更新日期:2010-08-20 00:00:00

  • Peficitinib: First Global Approval.

    abstract::Peficitinib [Smyraf® (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis. Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in...


    pub_type: 杂志文章,评审


    authors: Markham A,Keam SJ

    更新日期:2019-06-01 00:00:00

  • Drug treatment of scleroderma.

    abstract::Scleroderma or systemic sclerosis is a rare condition with many clinical manifestations including Raynaud's phenomenon. As with many other rarely encountered diseases, drug therapy for scleroderma is often empirical with little evidence in the form of randomised controlled trials to aid drug choice. Raynaud's phenomen...


    pub_type: 杂志文章,评审


    authors: Leighton C

    更新日期:2001-01-01 00:00:00

  • Managing cancer-related anorexia/cachexia.

    abstract::Cancer-related anorexia/cachexia (CAC) is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumour-derived catabolic factors, decreased food intake, and probably additional unknown factors, all play different roles. This review examines the...


    pub_type: 杂志文章,评审


    authors: Mantovani G,Macciò A,Massa E,Madeddu C

    更新日期:2001-01-01 00:00:00

  • Colloid volume expanders. Problems, pitfalls and possibilities.

    abstract::Colloid solutions have been developed and used over the past 70 years as expanders of the intravascular space, based on an understanding of Starling's law. Increasing osmotic pressure with colloidal products has remained an attractive theoretical premise for volume resuscitation. Indeed, colloids have been shown to in...


    pub_type: 杂志文章,评审


    authors: Roberts JS,Bratton SL

    更新日期:1998-05-01 00:00:00

  • Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.

    abstract::Irinotecan (CPT-II) is a semisynthetic derivative of camptothecin. It and other camptothecin analogues/derivatives appear to exert their antitumour activity by binding to topoisomerase I. The active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), has demonstrated potent growth inhibition of human col...


    pub_type: 杂志文章,评审


    authors: Wiseman LR,Markham A

    更新日期:1996-10-01 00:00:00

  • Etanercept: a review of its use in autoimmune inflammatory diseases.

    abstract::With its approval more than 15 years ago, subcutaneous etanercept (Enbrel(®)) was the first biological disease-modifying antirheumatic drug (bDMARD) and the first tumour necrosis factor inhibitor to be approved for use in rheumatic diseases. Etanercept remains an important cost-effective treatment option in adult pati...


    pub_type: 杂志文章,评审


    authors: Scott LJ

    更新日期:2014-08-01 00:00:00

  • The management of epilepsy in the 1990s. Acquisitions, uncertainties and priorities for future research.

    abstract::The pharmacological treatment of epilepsy has made considerable progress during the last decade, due to improved knowledge of the clinical pharmacology of individual drugs, acquisition of new information on the factors affecting response and need for drug treatment, and development of promising new agents. Once a clin...


    pub_type: 杂志文章,评审


    authors: Beghi E,Perucca E

    更新日期:1995-05-01 00:00:00

  • Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

    abstract::Zimelidine is a new antidepressant, which is structurally unrelated to the tricyclic and tetracyclic antidepressants. The pharmacological profile of zimelidine is different to that of other antidepressants in that it appears to owe the major part of its activity to the inhibition of serotonin uptake within the central...


    pub_type: 杂志文章,评审


    authors: Heel RC,Morley PA,Brogden RN,Carmine AA,Speight TM,Avery GS

    更新日期:1982-09-01 00:00:00

  • Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification.

    abstract::Although vasodilator drugs are of proven worth in the management of patients with severe heart failure, a useful system of classification of vasodilator drugs has not yet been devised. The traditional system of classification based on the dominant arterial and/or venous sites of action as determined by limb plethysmog...


    pub_type: 杂志文章,评审


    authors: Packer M

    更新日期:1982-07-01 00:00:00

  • Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.

    abstract::Resting heart rate is associated with cardiovascular and all-cause mortality, and the mortality benefit of some cardiovascular drugs seems to be related in part to their heart rate-lowering effects. Since it is difficult to separate the benefit of heart rate lowering from other actions with currently available drugs, ...


    pub_type: 杂志文章,评审


    authors: DiFrancesco D,Camm JA

    更新日期:2004-01-01 00:00:00